

Targeting on the values of Wolbachia endosymbionts as novel feasible anti-filarial chemotherapeutic approach to prevent/reduce /clear disease in lymphatic filariasis and interrupt transmission in endemic communities of Tanzania

Submission date 26/01/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 05/03/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 05/03/2009	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Achim Hoerauf

Contact details
Director, MD
Institute of Medical Microbiology, Immunology and Parasitology
University of Bonn, Faculty of Medicine
Sigmund Freud Str. 25
Bonn
Germany
53105
+49 (0)228 287 15675
hoerauf@microbiology-bonn.de

Additional identifiers

Study information

Scientific Title

Targeting on the values of Wolbachia endosymbionts as novel feasible anti-filarial chemotherapeutic approach to prevent/reduce/clear disease in lymphatic filariasis and interrupt transmission in endemic communities of Tanzania: a randomised double-blind placebo-controlled trial

Study objectives

Wolbachia endosymbionts bacteria are associated with inflammatory process in their human-host and filarial nematode causing overt clinical disease. However, the use of antibiotics with macrofilaricidal activity (doxycycline) that kills adult worms, might prevent or halt/cure/clear clinical disease such as lymphoedema (LE), acute dermatadenolymphangitis (ADLA) or acute filarial fevers with lymphangitis (AFL). In the present study, it will be investigated whether patients with ongoing infection (i.e., who are positive for circulating filarial antigen [CFA]) will benefit more, in the same way or less than patients without ongoing infection (i.e. CFA negative) but remaining pathology.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Medical Research Coordinating Committee of Tanzania approved on 11th November 2005 (ref: NIMR/HQ/R.8a/vol.IX/403)

Study design

Randomised double-blind placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Wuchereria bancrofti lymphoedema stage I - V

Interventions

45 individuals with circulating filarial antigen positive (CFA) and 45 individuals without circulating filarial antigen in their blood will be randomised to:

1. 200 mg/day doxycycline for 6 weeks
2. Placebo for 6 weeks

Contact details for co-investigator:

Dr WH Makunde

National Institute for Medical Research Tanga Centre

P.O. Box 5004

Tanga

Tanzania

Tel: +255 27 26 46084

Fax: +255 27 26 43869
E-mail hwmakunde@hotmail.com

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Doxycycline

Primary outcome(s)

1. Proportion of patients whose lymphoedema is reduced in size or cured
2. Proportion of acute filarial fevers and acute dermatadenolymphangitis episodes or subclinical episodes prevented or reduced or halted during the trial period
3. Levels of CFA reduced or cleared
4. Levels of vascular endothelial growth factors (VEGFs) and pro-inflammatory immunological responses in plasma pre-post treatment in different stages of LE individuals

Key secondary outcome(s)

1. The length of time taken for LE to change in size or cured or reappear again
2. The levels of anti-Wolbachia surface protein antibodies response at pre-post treatment
3. Tolerability of the anti-Wolbachia agent (antibiotic-doxycycline) (drug adverse events)

Completion date

21/11/2010

Eligibility

Key inclusion criteria

1. Age range 18 - 68 years
2. Males and females
3. Diagnosed clinically to have lymphoedema stages I - V
4. Permanent residents in the study area
5. May be microfilaraemia positive or negative

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Children and pregnant women
2. Chronic liver, kidney, cardiac, central nervous system disease
3. Allergy to the trial drugs
4. Previous history of using anti-filarial drugs, e.g. ivermectin, albendazole, diethylcarbamazine
5. Past history of taking anti-geohelminthics, e.g. mebendazole, and antibiotics such as tetracycline or rifampicin in the last six months

Date of first enrolment

27/09/2008

Date of final enrolment

21/11/2010

Locations

Countries of recruitment

Germany

Tanzania

Study participating centre

Director, MD

Bonn

Germany

53105

Sponsor information

Organisation

Volkswagen Foundation (VolkswagenStiftung) (Germany)

ROR

<https://ror.org/03bsmfz84>

Funder(s)

Funder type

Research organisation

Funder Name

Volkswagen Foundation (VolkswagenStiftung) (Germany)

Alternative Name(s)

VolkswagenStiftung, The Volkswagen Foundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Germany

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary